Christopher (Chris) Turner, M.D. is an experienced oncology drug developer and executive with over 20 years of clinical and pharmaceutical experience in both early and late stage oncology drug development. He joined Nuvalent in March 2021 as Chief Medical Officer.
Before joining Nuvalent, Dr. Turner was Vice President of Clinical Development at Blueprint Medicines, where he oversaw the development and approval of kinase inhibitor GAVRETO™ (pralsetinib) in RET fusion positive non-small cell lung cancer (NSCLC) and RET altered thyroid cancer. Additionally, Dr. Turner oversaw development programs targeting the FGFR4 kinase and EGFR with emergent resistance mutations.
Dr. Turner previously led the development of novel ADC and immune-oncology pipeline compounds at Celldex Therapeutics, and the clinical development at Ariad Pharmaceuticals of two kinase inhibitor therapies that have since been approved for patients with cancer, ICLUSIG® (ponatinib) for patients with chronic myeloid leukemia, and ALUNBRIG® (brigatinib) for patients with ALK-positive NSCLC.
Prior to that, Dr. Turner was Director of the Pediatric Neuro-Oncology Outcomes Clinic at the Dana-Farber Cancer Institute/Children’s Hospital Boston and an Instructor of Pediatrics at Harvard Medical School where he treated children and young adults with brain tumors.
Dr. Turner is double board certified in both Pediatrics and Pediatric Hematology and Oncology and is a Fellow of the American Academy of Pediatrics. He received his M.D. from the University of Rochester School of Medicine and Dentistry in Rochester, New York. He completed fellowships in both Pediatric Hematology/Oncology and Pediatric Neuro-Oncology at Duke University Medical Center in Durham, North Carolina.
What is Christopher Durant Turner's net worth?
The estimated net worth of Christopher Durant Turner is at least $970,339.18 as of October 4th, 2023. Dr. Turner owns 14,513 shares of Nuvalent stock worth more than $970,339 as of April 28th. This net worth approximation does not reflect any other assets that Dr. Turner may own. Additionally, Dr. Turner receives a salary of $714,260.00 as Insider at Nuvalent. Learn More about Christopher Durant Turner's net worth.
How old is Christopher Durant Turner?
What is Christopher Durant Turner's salary?
As the Insider of Nuvalent, Inc., Dr. Turner earns $714,260.00 per year. The highest earning executive at Nuvalent is Dr. James R. Porter Ph.D., CEO, President & Director, who commands a salary of $998,020.00 per year. Learn More on Christopher Durant Turner's salary.
How do I contact Christopher Durant Turner?
Has Christopher Durant Turner been buying or selling shares of Nuvalent?
Christopher Durant Turner has not been actively trading shares of Nuvalent over the course of the past ninety days. Most recently, Christopher Durant Turner sold 7,995 shares of the business's stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $54.04, for a transaction totalling $432,049.80. Following the completion of the sale, the insider now directly owns 14,513 shares of the company's stock, valued at $784,282.52. Learn More on Christopher Durant Turner's trading history.
Who are Nuvalent's active insiders?
Are insiders buying or selling shares of Nuvalent?
During the last year, insiders at the sold shares 35 times. They sold a total of 1,466,651 shares worth more than $103,203,548.94. The most recent insider tranaction occured on April, 22nd when Director Matthew Shair sold 37,500 shares worth more than $2,386,875.00. Insiders at Nuvalent own 14.8% of the company.
Learn More about insider trades at Nuvalent. Information on this page was last updated on 4/22/2024.
